Note: You are reading this message either because your browser is not standards-compliant, or your browser failed to load our css files.

 
 

Market Summary

Dow 11349.28 -283.10 (-2.43%)
Nasdaq 2280.11 -45.77 (-1.97%)
Russell 2K 702.39 +0.00 (+0.00%)
S&P 500 1252.54 -29.65 (-2.37%)
S&P 100 579.09 +0.00 (+0.00%)
Quotes are delayed 20 minutes.

Current Targets and Stops

Symbol Picked ST SSL
AAPL $93.00 $225.00 $175.00
CPNE $0.50 $4.50 $1.45
CREE $25.00 $50.00 $23.00
EFSF $0.18 $0.50 $0.16
NIHK $0.04 $0.13 $0.08
PNWIF $1.80 $6.00 $3.00
QID $38.67 $42.19 $35.00
RIMM $115.00 $120.00 $112.00
SPKL $0.69 $2.00 $0.90
TCGD $0.87 $2.00 $0.65
TTGL $0.84 $3.00 $1.73
ST Denotes Suggested Target.
SSL Denotes Suggested Stop Loss.
Click Here to View the V2K International Video Presentation
Free Annual Reports

OTC Blog

OTC Journal RSS Content

The OTC Journal content is also available via RSS feeds, viewable with an RSS or Atom capable client.

Don't miss an article. Click Here for complete instructions on how to add our RSS feeds to your Outlook or Internet Explorer.

  March 6, 2008  
  Volume IX, Issue 17  
Home Page : www.otcjournal.com
Email Questions or Comments To: editor@otcjournal.com

To OTC Journal Members:
 

eFoodSafety (OTC BB: EFSF): The Winds Of Change Are About To Howl

I cover a number of situations in the OTC Journal, but the one I get most questions, observations, whining, and complaining about is eFoodSafety. It's probably because of the unmet expectations in 2007. Whether the company was too optimistic, or the market jumped ahead of itself, investors have been very frustrated. People who have looked at EFSF are excited about their product line, but simply can't understand why they have been relatively unsuccessful getting their products in the hands of the consumer.

A year ago investors looked at their odds, and placed their bets. It's like the frustration one feels at the blackjack table when you have 2 face cards, and the dealer draws 5 cards to 21. Sometimes, it's just not fair.

So, as long as we're into card metaphors, lets call a spade a spade. When I first looked at their product line in late 2006 and learned the retail names that would carry their products, I believed the stock would be an easy winner. Here's the reality- selling their products to retail consumers through chains like WalMart and Rite Aid have been a disappointment relative to expectations. Investors have been expressing their chagrin: not only vocally and digitally, but through the ultimate expression of dissatisfaction- liquidating positions.

As we turned the corner into 2008, I wrestled with where to go with this one. Should I abandon the coverage, and move on to greener pastures? Or stay with them for another year and see what happens.

We ended up extending our relationship, and I have agreed to continue to cover their progress for one compelling reason: I have renewed enthusiasm for the idea. We all have challenges. Plans we make go awry. It's going to happen, and your character is not measured by the challenges. It is measured by how you respond to the challenges. EFSF is turning in a new direction to insure those exciting products get in the hands of consumers. Respond2, a highly successful direct marketing advertising agency, is taking the reins on 3 of their ready for market products, and we are a few short weeks away from campaign launch.

Today's presentation is for you: the shareholders, potential shareholders, and interested parties. I believe knowledge is power, and power can turn into profits. Today, I am going to provide you with knowledge that could help you make a lot of money in EFSF from the current levels. You have to listen or read and decide for yourself.

In looking at the company, I felt the single best thing that could happen would be for sales to hit the $10 million mark in 2008, and for the company to turn cash flow positive on an ongoing basis. Once EFSF achieves significant positive cash flow, the company will have the luxury of time to get their wild card products to market without diluting current shareholders- these include Citroxin as a possible therapy for Bird Flu and MRSA Staph, Oraphtye for the bio agricultural world, and PurEffect (which is taking forever, much to the disappointment of shareholders- more on that one later).

Today, you will have the advantage of listening to or reading an interview I conducted with Tim O'Leary, the CEO of Respond2. Respond2 is the direct marketing advertising company that is launching campaigns for Cinnergen, Cinnechol, and the new nano technology ski care product NumaDerm.

The interview runs about 15 minutes. Make a no-risk decision to invest 15 minutes of your time. For starters, your computer has to have speakers, so turn them up before clicking on the link. If you get an error message, our server might be overloaded, so try again in a few minutes. If you don't have speakers, you can read the text below.

I believe the company has made the right move, and now has a real shot at becoming something special. You have a unique opportunity to understand how Respond2 does it, listen to the plan and make up your own mind once you are armed with the knowledge.

After all, even the dealer can't draw 5 cards to 21 every time. Perhaps it's time for the players to win one.

I am very interested in your feedback on this content. To that end, I have posted a new BLOG specifically for your comments on Respond2, the direction of the company, and any other EFSF related issues. Once you have finished with the interview, please visit the BLOG on the home page and share your thoughts, or just click here for a direct route. Alternatively, you can email me at editor@otcjournal.com.

Click Here
To Hear the Interview
or copy and post following URL into your browser: 
http://www.otcjournal.com/efsf/

or, read the text below:
 

OTCJOURNAL.COM

Moderator: Larry Isen
February 26, 2008
3:00 pm CT
Interview with Tim O'Leary, CEO of Respond2

Larry Isen: Hi. My name is Larry Isen and I am the Editor and Publisher of the OTC Journal, an Internet portal specializing in micro cap stocks. I've been covering eFoodSafety since January of 2007.

 I was originally compelled by their unique product offerings and their natural approach to product development. This theme fits very well with growing consumer demand for less toxic wellness products.

 The growth of companies like Whole Food Markets over the past five years serves as proof there is a megatrend towards much healthier choices in our lives.

 Like other eFoodSafety shareholders I was disappointed in the company's ability to get their products sold to consumers throughout 2007. I had high hopes earlier in the year but as the numbers rolled in throughout the course of '07 it became clear their distribution through large retail chains wasn't working out as well as we all hoped.

 To their credit eFoodSafety is tackling the problem and moved in a new direction for 2008. Respond 2 -- a unique direct response advertising agency -- will launch campaigns for three of their products beginning sometime in March. Respond2 will initiate campaigns for Cinnergen, Cinnechol and NumaDerm.

 As shareholders it's valuable for all of us to understand the potential for improving product sales. To that end I've invited Tim O'Leary -- the CEO of Respond2 -- to talk about his agency and how they work.

 Tim thanks a lot for joining us today. I want to start by asking you to describe Respond2's unique programs and tell us how they differ from the standard Madison Avenue style advertising agency.

Tim O'Leary: Sure. Happy to do it. In the traditional world of advertising the effectiveness of advertising is based on the - how people perceive the creative and essentially how many eyeballs see the creative, how many people see it.

 Our approach is quite a bit different in that we are a branded direct response agency which essentially means that we take the methodologies of direct response advertising but we work with major brands so that you get the efficiencies of direct response advertising and the impact of traditional branding.

 So how this would really differ is that as opposed to how many people see an ad and how clever or how many awards the creative wins for that ad what we really care about is how many people respond.

 So the creative is structured a little bit differently. It's more about salesmanship and explanation than it is just sort of interesting creative. We really attempt to sell the product. We shoot our commercials with all the production quality that you would have in a major production so that you get that good feeling about the brand.

 And the spots tend to be longer. As opposed to 15 or 30 seconds which you have with the traditional commercial we tend to work in the 60 second to 120 second range.

 And then the big thing is that at the end of every commercial you have what we call a call to action. So we drive the consumer to take a response. Typically that response is to go on-line or call a toll-free number and purchase the product or get more information.

 All this is measured then. And our media measurement is based on a cost per inquiry and a conversion to order so that at the end of the day as opposed to again being judged by those traditional brand metrics we're really judged on was the creative efficient. Did people like it? Did they understand the product and did they buy the product.

 And so we specialize in building all the systems. And that involves obviously coming up with the creative and the brand template; producing the commercial; building the back end systems which includes the right kind of telemarketing, the right kind of website; helping establish fulfillment; and then purchasing media that is ideal to hit that demographic; and then finally tracking it.

 So when you're a client of ours you get a report everyday that tells you exactly what happened to your advertising dollars the day before. And it's kind of the television equivalent of on-line marketing because we optimize. If we're doing well in certain media channels then we spend more on those media channels. If we're not doing well then we cut back. And we're able to get a daily read on how the advertising is doing.

Larry Isen: So you guys get live - real daily reports on exactly what result the advertising is creating.

Tim O'Leary: Exactly. Typically now about 50% of consumers when they see a direct response advertisement will use the web as opposed to telemarketing which is great because it's a more efficient way to handle the orders. So we have real-time reporting on that and we can see what's going on.

 The other thing that happens is that there's an enormous halo effect to this kind of advertising. Because you really are getting, you know, all the benefits of traditional advertising. People are seeing the commercials.

 And if they aren't buying, you know, per the - what we say in the call to action you do see enormous upswing at retail and, you know, in all the other channels where the product is available.

 So if the campaign works and it's orchestrated right it really gives you the most bang for your buck.

Larry Isen: Tim can you talk about the agency a little bit? Tell us how many employees you have, how many branches, how much media, your annual purchase…

Tim O'Leary: Sure. We are based in Portland, Oregon. And in Portland we have a large media operations. We have in-house production. We have web and on-line optimization.

 We also have a big media operation in Philadelphia, in Providence, Rhode Island. We have branch buyers in Los Angeles and Chicago. And we will soon be coming on-line with a new operation in California.

 So right now we are about 200 full-time employees. And last year we bought somewhere between $300 and $350 million in media.

Larry Isen: Tim can you talk a little bit about some of the products you've represented in the past and what kind of successes your clients enjoyed?

Tim O'Leary: Sure. Well we have a wide range of clients that kind of go from traditional direct response clients to major brands that use direct response. So, you know, current and past clients have included, you know, big packaged goods companies like Clorox and P&G.

 We do a lot in the health and beauty arena so Bare Essentials is a client. Philosophy is a client in those arenas. Some of the more traditional branded direct response direct marketers - we just took over the Bowflex Nautilus account.

 And then we work a lot in financial services and telecommunications. We're agency of record for Vonage and have been for about nine months and have really made great headway there making their marketing more efficient. Philips Electronics, Home Depot, a lot of different kinds of companies.

 But the commonality is that we are always working with a very specific cost per inquiry, cost per order metric. And so it could be a major brand that uses us as their direct agency or we could be agency of record for an entire brand if they measure on those kind of metrics.

Larry Isen: Tim can you - can you maybe identify a couple of products that you've represented in the past or do currently that are kind of similar to the wellness products that eFoodSafety is going to be offering and tell us if you've had some success with those?

Tim O'Leary: Sure. Probably the most analogous campaign is for a number of years we were doing the direct response television campaigns for Pharmavite which owns Nature Made vitamins and a number of - they develop a number of condition specific nutraceuticals. So we worked on Cholest Off and Stress Ease - a number of different products like that for several years and they spent many many millions in direct response television.

 That was very similar in the kind of products we were selling. The difference was that they chose instead of direct selling to drive their retail distribution because they have quite enormous retail distribution.

 So we would invite consumers to call and get a coupon and then we would track the coupon usage. And driving through, you know, big (unintelligible) like Costco and companies like that. But in terms of the messaging of the campaign they would be the most similar.

 Other kinds of clients - this will be what we call a continuity campaign which is in our world sort of the gold standard if you can make it work. So a lot of makeup clients - again Bare Essentials which is one of the biggest direct response advertisers. They sell people into continuity beauty programs. But they also really want to drive their retail distribution in Sephora and premium retailers.

 So my guess is that if all goes well with eFoodSafety we will have a combination campaign where we will hopefully successfully run continuity on the front end. But they're going to see again that big halo effect at retail.

Larry Isen: Can you talk to us a little bit about the technologies and the metrics you use to measure the success of your direct response campaigns?

Tim O'Leary: Sure. At its simplest we are looking again for a cost per inquiry, a conversion to order, an average order, and in this case what we would call a lifetime valuation. So everything is keyed against that.

 We will have a target number to get a consumer to call or click. And that is a function of how well your creative and your media is done. Once we get them to do that we have another target ratio as to the percentage of those consumers that buy the product and how much they initially buy of the product. And that's a function of how you manage what we call the back end of the campaign.

 And then the final thing is the lifetime valuation of that client. And that is how many orders do they continue to receive as part of the program. And that becomes again a back end management and really a quality of product issue for consumers.

Larry Isen: And what kinds of midstream adjustments might you make if a campaign is - you know, if you're trying to fine tune a campaign to maximize the result?

Tim O'Leary: Well this is really a testing medium. And I always prepare clients for this because it can take you a while. Sometimes you hit it out of the ballpark on the very first campaign. And I've had other campaigns it's taken as long as a year to test.

 So the beauty of this is you don't have to spend a lot of money during the testing process. And then the testing process will tell you how much you can spend.

 But you are - you tend to test in two week increments. And I would say on an average you might test a couple to three creative configurations, you know, before you find exactly the right creative. And that would be how does the commercial come together and what's the right offer configuration and call to action.

 Once you have that sort of worked out -- and the offer configuration is really sort of a crucial part of it -- then you have to fine tune things like obviously it's more cost efficient to drive people to the web. So you need to get your website really pumping right. We specialize in building websites that are specifically designed for direct response.

 You have to have your customer service right. You don’t want to sign up too many people into a program until you kind of work out the (nits) and make sure that you have a very happy client.

 The other thing that becomes an important part of this is that most consumers now research quite a bit. And so we get very involved in all the relationship marketing aspects of the campaign including blogs, analyzing, you know, what competitors are saying, peer reviews, expert reviews, all those kinds of things that help us convert more people into buyers and then making sure that the clients are happy - the customers are happy and stay on the product for as long as possible.

Larry Isen: So in the case of say Cinnechol and Cinnergen these are two products you'll be introducing that have actual clinical trials that measure their capability for generating results…

Tim O'Leary: Exactly.

Larry Isen: Those will become powerful tools for you guys?

Tim O'Leary: That is real powerful and it's essential. There are, you know, certain - actually quite a few restrictions on, you know, the kind of claims we can make on television.

 And we're very specific on behalf of our clients and, you know, our own situation to make sure that all the claims are valid, can be backed up. The station's networks have different requirements for substantiation.

 What really makes these things work -- and I tell clients all the time -- is that if you have strong clinicals and you have very strong real testimonials that can substantiated that goes a long way in making a campaign successful.

 And I would, you know, a high percentage of the clients that come to us don't have that.

Larry Isen: So in the case of eFoodSafety they have both of those I assume, right?

Tim O'Leary: They do. They have strong clinicals and they have a good story to tell and good testimonials. It's nice because it's an established product that's been out there a while. So, you know, our job is to translate that into a compelling story for what we think is a pretty broad target demographic.

Larry Isen: Do you guys have a time table now for the launch of the initial campaigns for their products?

Tim O'Leary: We are shooting Cinnergen and Cinnechol as we speak this week. And I don't have the specific time table in front of me but there's about - once we finish shooting this week and we'll be shooting all week there's normally sort of a four to six week editorial and distribution process.

 We're building the websites. I was just approving the website copy this morning. And so we're moving full steam ahead on those two products. And, you know, you will see those campaigns launch within a few weeks.

Larry Isen: And for those of you who are listening just to clarify - I'm doing this interview with Tim about 1:00 Western Time - Pacific Time on the 26 of February - Tuesday.

 So that would imply that maybe towards the end of March/early April we'll actually start seeing these things appear in media. Would that be…

Tim O'Leary: Yeah I believe we have a March - we have a late March launch on these.

Larry Isen: Well Tim I can't thank you enough for your time. Thanks so much. You know, we're all rooting for great success in these product introductions. And for you investors who are listening or reading I think you have a good feel now for eFoodSafety's approach to its biggest challenge.

 I hope you found this information valuable. Thank you for your time.

END
 

 
  Subscribe  

Information is power and timely information is profitable. Become informed and profit from OTC Journal Profiles and Trading Alerts by becoming a Preferred Member today. There is no cost associated with your email subscription. Add your email address below and make sure to check your email inbox and confirm your opt-in request to start receiving the OTC Journal Email Newsletter on a regular basis.

To ensure newsletter delivery, you can add any additional email addresses you may have to the OTC Journal Member List. Receiving the OTC Journal Newsletter in multiple locations is the best way of making sure you don't miss the next investing or trading opportunity! For web based email addresses, the OTC Journal recommends @yahoo.com or @aol.com for timely and reliable email newsletter delivery.

Subscribe Here

Note: Your email address will be kept strictly confidential, and will not be shared with any other entity for any purpose at any time. If you no longer wish to receive the OTC Journal, simply follow the instructions located at the bottom of every OTC Journal Newsletter Edition.

  Refer A Friend  

If you find the OTC Journal informative and profitable, please forward our newsletter alert service to like-minded friends and associates who share similar market interests.


  Ensure Newsletter Delivery  

To ensure newsletter delivery, you can add any additional email addresses you may have to the OTC Journal Member List. Receiving the OTC Journal Newsletter in multiple locations is the best way of making sure you don't miss the next investing or trading opportunity! For web based email addresses, the OTC Journal recommends @yahoo.com or @aol.com for timely and reliable email newsletter delivery.

Note: Your email address will be kept strictly confidential, and will not be shared with any other entity for any purpose at any time. If you no longer wish to receive the OTC Journal, simply follow the instructions located at the bottom of every OTC Journal Newsletter Edition. 

Disclaimer
The OTC Journal Newsletter is an independent electronic publication committed to providing our readers with factual information on selected publicly traded companies. All companies are chosen on the basis of certain financial analysis and other pertinent criteria with a view toward maximizing the upside potential for investors while minimizing the downside risk, whenever possible. Moreover, as detailed below, this publication accepts compensation from certain of the companies which it features. Likewise, this newsletter is owned by MarketByte, LLC. To the degrees enumerated herein, this newsletter should not be regarded as an independent publication.

Go Here to view our compensation on every company we have ever covered, or visit the following web address: http://www.otcjournal.com/disclosure/compensation/section/profile/ for our full profiles and http://www.otcjournal.com/disclosure/compensation/section/alert/ for Trading Alerts. MarketByte LLC has been paid a fee of $30,000 cash and 1 million newly issued restricted shares by eFoodSafety for coverage of the company. On January 17, 2008, eFoodSafety engaged MarketByte LLC for a one year extension of its coverage. The original 1 million shares have become free trading under Rule 144 as of January 17, 2008. Additionally, the Managing Member of Marketbyte LLC has purchased 50,000 shares of eFoodSafety in the open market at an average cost basis of $.19 cents per share.

All statements and expressions are the sole opinions of the editors and are subject to change without notice. A profile, description, or other mention of a company in the newsletter is neither an offer nor solicitation to buy or sell any securities mentioned. While we believe all sources of information to be factual and reliable, in no way do we represent or guarantee the accuracy thereof, nor the statements made herein.

From time to time MarketByte, LLC sells shares in the open market it receives as compensation for coverage of client companies. Since the shares are received as compensation for services as previously disclosed, and not for investment purposes, the editors do not view the sale of the shares as contradictory to any advice delivered in the content. This should be viewed as a conflict of interest by shareholders or prospective shareholders of the client companies.

The editor, members of the editor's family, and/or entities with which they are affiliated aside from MarketBtye LLC itself, are forbidden by company policy to own, buy, sell or otherwise trade stock for their own benefit in the companies who appear in the publication unless specifically disclosed in the newsletter.

The Trustee of the MarketByte, LLC Defined Benefit and Trust (“the MarketByte Pension Plan”) has invested approximately $310,0000 in the Longview Fund (“the Longview Limited Partnership”), a limited partnership in which the MarketByte Pension Plan is a limited partner. No one associated with the MarketByte Pension Plan has any knowledge, information, or control as to any past, present, or future investment activities of the Longview Fund. Longview ocassoinally refers companies to MarketByte, LLC for possible coverage by one of the MarketByte, LLC publications, which publications include the OTC Journal Newsletter. Longview may or may not own shares in the companies that it so refers to MarketByte. MarketByte has no information (outside of information readily accessible to the general public such as SEC filings) as to whether Longview owns any shares in the companies that it refers to MarketByte, LLC. The above relationships should be viewed as a potential and/or actual conflict of interest by shareholders and prospective shareholders of MarketByte, LLC client companies. 

The profiles, critiques, and other editorial content of the OTC Journal may contain statements that appear foward relating to the expected capabilities of the companies mentioned herein.

THE READER SHOULD VERIFY ALL CLAIMS AND DO THEIR OWN DUE DILIGENCE BEFORE INVESTING IN ANY SECURITIES MENTIONED. INVESTING IN SECURITIES IS SPECULATIVE AND CARRIES A HIGH DEGREE OF RISK. THE INFORMATION FOUND IN THIS PROFILE IS PROTECTED BY THE COPYRIGHT LAWS OF THE UNITED STATES AND MAY NOT BE COPIED, OR REPRODUCED IN ANY WAY WITHOUT THE EXPRESSED, WRITTEN CONSENT OF THE EDITORS OF OTCJOURNAL.COM.

We encourage our readers to invest carefully and read the investor information available at the web sites of the Securities and Exchange Commission ("SEC") at http://www.sec.govand/or the National Association of Securities Dealers ("NASD") at http://www.nasd.com. We also strongly recommend that you read the SEC advisory to investors concerning Internet Stock Fraud, which can be found at http://www.sec.gov/consumer/cyberfr.htm. Disclaimer ID: Readers can review all public filings by companies at the SEC's EDGAR page. The NASD has published information on how to invest carefully at its web site. MarketByte LLC's mailing address is 4653 Carmel Mtn Rd Suite 308 #402, San Diego, CA 92130.


You can unsubscribe from this list at any time by Clicking Here. If you are having difficulty removing yourself or wish to change your address please go to http://www.otcjournal.com/opt/?.

 

Having Trouble Getting Our Email Newsletter?

White List Us. Click Here for more info...
Click Here to View the Spicy Pickle Video Presentation

Latest Blog Entries

Mon, Jul 21, 2008 @ 09:35 pm
It was a pretty ho hum day. The day started out reasonably strong as B of A came out and announced much lower write downs than the market had anticipated. Financials were up early, and carried the market a bit higher. The larger financial institutions are not doing as badly as the market would have [...]
Mon, Jul 21, 2008 @ 09:21 pm
I know there hasn’t been a lot to chew on out of EFSF of late. I have been briefed on developments at the company. The DR program is being fine tuned, and they will be back out there soon with a bigger commitment. There was an article that appeared in a recent edition of Equities Magazine. [...]
Wed, Jul 16, 2008 @ 01:18 pm
Oil, oil, oil, oil. Huge bank rally today along with the first decent up day in the larger markets in the last month. The S&P 500 has dropped 220 points and the DOW has dropped 2,000 points since we’ve had a decent up day like this. One decent day in the larger market does not make [...]

Recent Newsletter Editions

Wed, Jul 23, 2008 @ 07:28 pm
Oil and Platina- Should They Correct Together? The market is improving nicely as oil starts a corrective phase after one of the most prolific parabolic runs in the history of markets. Oil peaked at nearly $150, and closed at about $124 today- so much for the idea that the price of oil was simply a function...
Sat, Jul 19, 2008 @ 08:07 pm
Comments in the BLOG For all of you who were following the trading strategy I laid out in last weekend's edition for shorting large caps into earnings releases, you probably have figured out by now that I have pretty much abandoned that idea. The Daily BLOGs have contained no short term trading ideas...
Thu, Jul 17, 2008 @ 11:23 am
Spicy Pickle (OTC BB: SPKL) Notches #42 SPKL announced store #42 is now open for business. It is located in Michigan- Portage, Michigan to be precise. Michigan represents the 14th state for Spicy Pickle. The Michigan franchisee has committed to opening 10 stores in the Kalamazoo- Grand Rapids- Ann Arbor...